CompumedicsASX:CMP -7.41%62 Debt-to-Equity is 0.57 as of Dec. 2025, which is 68% above its 10-year median of 0.34. GuruFocus rates ASX:CMP with a GF Score™ of 62/100 and a GF Value™ of A$0.32 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 704 Medical Devices & Instruments companies, Compumedics ranks worse than 72.16% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Compumedics's Debt-to-Equity or its related term are showing as below:
ASX:CMP'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.34 Max: 0.89
Current: 0.57
During the past 13 years, the highest Debt-to-Equity Ratio of Compumedics was 0.89. The lowest was 0.04. And the median was 0.34.
ASX:CMP's Debt-to-Equity is ranked worse than 72.16% of 704
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs ASX:CMP: 0.57
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Compumedics Debt-to-Equity Related Terms
Compumedics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Compumedics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CMP vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Compumedics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compumedics Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Compumedics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Compumedics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compumedics (ASX:CMP) has a Debt-to-Equity of 0.57 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Compumedics and its competitors. This is 68% above median its historical median of 0.34. Over the past decade, Compumedics' Debt-to-Equity has ranged from 0.04 to 0.89. According to the industry distribution chart, Compumedics ranks #508 out of 704 companies in the Medical Devices & Instruments industry, placing it in the top 72.2%.
Is Compumedics' Debt-to-Equity too high?
Compumedics' current Debt-to-Equity of 0.57 is 68% above median its 10-year median of 0.34. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 0.89. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Compumedics' value of 0.57 is 147.8% above this industry median. Based on the distribution chart, Compumedics ranks #508 out of 704 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Compumedics has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Compumedics' Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Compumedics ranks #508 out of 704 companies for Debt-to-Equity. This places Compumedics in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Compumedics' value of 0.57 is 147.8% above this benchmark. Historically, Compumedics' own Debt-to-Equity has ranged from 0.04 to 0.89 over the past decade. While the company's 10-year median is 0.34 vs. the industry median of 0.23, Compumedics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Compumedics's current Debt-to-Equity of 0.57 is 147.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Compumedics and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compumedics's current Debt-to-Equity is 0.57, which is 68% above median its own 10-year median of 0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compumedics stock overvalued right now?
Based on GuruFocus' analysis, Compumedics (ASX:CMP) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.32, compared to a current price of A$0.25 — trading 21.9% below its estimated fair value. The current Debt-to-Equity is 0.57, which is 68% above median its 10-year median of 0.34 and 147.8% above the Medical Devices & Instruments industry median of 0.23. Compumedics' overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Compumedics (ASX:CMP), the current Debt-to-Equity is 0.57 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Compumedics (ASX:CMP) Overvalued in 2026?
Based on GuruFocus' analysis, Compumedics stock appears to be undervalued.
The current stock price of A$0.25 is trading 21.9% below its estimated GF Value™ of A$0.32.
GuruFocus considers Compumedics to be Modestly Undervalued.
Key valuation signals for ASX:CMP:
Debt-to-Equity: 0.57 (68% above median its 10-year median of 0.34)
GF Value™: A$0.32 vs. price of A$0.25 (21.9% below fair value)
Industry Position: 147.8% above the Medical Devices & Instruments median (#508 of 704)
No single metric tells the full story. See the ASX:CMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Compumedics Ltd is a medical device company. It is engaged in the development, manufacturing, and commercialization of diagnostic technologies for sleep, brain, and ultrasonic blood-flow monitoring applications. The company is organized into geographical operating segments, being the United States of America, Australia and Asia Pacific, and Europe and the Middle East. It derives a majority of its revenue from Australia and the Asia Pacific region.
62GF Score
Get the complete analysis for ASX:CMP
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CMP has been successfully added to your 
